Vasculitis & polymyalgia rheumatica
COVID-19 Vaccination as a Trigger of IgA Vasculitis: A Global Pharmacovigilance Study
Authors' conclusion
This study provides reassuring results regarding the safety of COVID-19 vaccines in the occurrence of IgAV compared to other vaccines.
Study context
- Population
- Cases of de novo igA vasculitis (IgAV) reported after COVID-19 vaccines in VigiBase, 24 countries330 COVID-19 vaccine IgAV cases · 24 countries
- Comparison
- COVID-19 vaccines vs all other drugs and vs other vaccines
- COVID-19 vaccinesn = 330
- Other vaccinesn = 996reference
- Outcome
- Disproportionate reporting of IgAV (IC)
Methodological detailsdisproportionality analysis of VigiBase, global, Bayesian information component
- Disproportionality analysis of VigiBase
- Global
- Bayesian information component
Main finding
As reported in the abstract
Disproportionate reporting of IgAV
Information component (IC)
0.22
95% CrI 0.04–0.35
COVID-19 vaccines vs All other drugs · CrI; small significant increase
IC
−1.42
95% CrI −1.60 to −1.28
COVID-19 vaccines vs Other vaccines · CrI; no disproportionality signal
Further findings
Case characteristics (COVID-19 vaccines)
- Female
- 163/328 (50%)
- Median age, years (IQR 15-59)
- 32
- Young (1-17 yrs)
- 84/254 (33%)
- Median time to onset, days (IQR 2-16; n = 256)
- 7
- mRNA vaccines
- 280/330 (85%)
- Positive rechallenge
- 3 of 4 (75%)
mRNA vs viral vector COVID-19 vaccines
- No significant difference
Overreporting by sex and age
- Men and children had significant overreporting of IgAV vs women and adults, respectively
Safety
Seriousness and outcome of IgAV cases
- Serious
- 188/324 (58%)
- Recovered
- 95/147 (65%)
- Died
- 2/147 (1%)
Original publication
COVID-19 Vaccination as a Trigger of IgA Vasculitis: A Global Pharmacovigilance Study. J Rheumatol. Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →